Xenetic Biosciences Inc. (NASDAQ:XBIO) price on Thursday, August 26, fall -0.64% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.12.
A look at the stock’s price movement, the close in the last trading session was $3.14, moving within a range at $3.08 and $3.27. The beta value (5-Year monthly) was 2.53. Turning to its 52-week performance, $5.85 and $0.76 were the 52-week high and 52-week low respectively. Overall, XBIO moved -2.80% over the past month.
Xenetic Biosciences Inc.’s market cap currently stands at around $30.33 million, with investors looking forward to this quarter’s earnings report slated for Nov 13, 2020. Analysts project the company’s earnings per share (EPS) to be -$0.16, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.55 and about -$0.37 for fiscal year 2022. Per the data, EPS growth is expected to be 67.60% for 2021 and 32.70% for the next financial year.
Analysts have a consensus estimate of $190k for the company’s revenue for the quarter, with a low and high estimate of $190k and $190k respectively. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $800k, representing a 83.10% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that XBIO is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend XBIO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
XBIO’s current price about -12.04% and 15.72% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.75, while 7-day volatility ratio is 7.48% and 20.17% in the 30-day chart. Further, Xenetic Biosciences Inc. (XBIO) has a beta value of 2.58, and an average true range (ATR) of 0.64. Analysts have given the company’s stock an average 52-week price target of $5.00, forecast between a low of $5.00 and high of $5.00. Looking at the price targets, the low is -60.26% off current price level while to achieve the yearly target high, price needs to move -60.26%. Nonetheless, investors will most likely welcome a -60.26% jump to $5.00 which is the analysts’ median price.
In the market, a comparison of Xenetic Biosciences Inc. (XBIO) and its peers suggest the former has performed considerably weaker. Data shows XBIO’s intraday price has changed -0.64% in last session and 176.11% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.58% and -0.54% respectively in the last trading.
If we refocus on Xenetic Biosciences Inc. (NASDAQ:XBIO), historical trading data shows that trading volumes averaged 1.51 million over the past 10 days and 10.02 million over the past 3 months. The company’s latest data on shares outstanding shows there are 8.75 million shares.
The 10.58% of Xenetic Biosciences Inc.’s shares are in the hands of company insiders while institutional holders own 4.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 71360.0 on Apr 14, 2021, giving us a short ratio of 0.36. The data shows that as of Apr 14, 2021 short interest in Xenetic Biosciences Inc. (XBIO) stood at 0.82% of shares outstanding, with shares short falling to 0.13 million registered in Mar 14, 2021. Current price change has pushed the stock 52.94% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the XBIO stock continues to rise going into the next quarter.